ProForma 2.0
validated simple linear
RKKRRQRRRGGGGVTDFGVFVEI
R23IT
Aliases: R23IT
Normalized sequence
RKKRRQRRRGGGGVTDFGVFVEI
23 amino acids
Release PepDiana-V1-20260620
36
Activity records
1
Source papers
23
Positive
13
Negative / threshold
Versioned scientific descriptors
No separate physicochemical property was reported in the primary-literature identity record. PepDiana release values are shown as computed properties.
Molecular weight
2675.0633 Da
Molecular formula
C115H196N44O30
Theoretical pI
12
Net charge at pH 7
5.762
GRAVY
-1.1
Instability index
120.6348
Aromaticity
0.087
Topological polar surface area
1264.88 Ų
cLogP
-14.4562
Hydrogen-bond donors
48
Hydrogen-bond acceptors
36
Rotatable bonds
95
Method: PepDiana sequence/structure descriptor pipeline
Tool: Biopython+RDKit · Biopython 1.85; RDKit 2024.09.6
Calculated: 2026-06-20T11:01:38.358971+00:00
Assumptions: ph=7; termini=free N-terminus and free C-terminus for simple linear peptides; stereochemistry=standard L-amino acids; smiles_length_limit=200
ProForma 2.0
validated simple linear
RKKRRQRRRGGGGVTDFGVFVEI
HELM 2.0
validated simple linear
PEPTIDE1{R.K.K.R.R.Q.R.R.R.G.G.G.G.V.T.D.F.G.V.F.V.E.I}$$$$V2.0
Canonical SMILES
validated
CCC(C)C(NC(=O)C(CCC(=O)O)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(Cc1ccccc1)NC(=O)C(CC(=O)O)NC(=O)C(NC(=O)C(NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(N)=O)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(N)CCCNC(=N)N)C(C)C)C(C)O)C(C)C)C(C)C)C(=O)O
Isomeric SMILES
validated
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(=N)N)C(C)C)[C@@H](C)O)C(C)C)C(C)C)C(=O)O
Paper-level observations
Table 1: R23I^T against MRSA (SA 180-F Strain) shows ↓ (1 mg/mL).
Table 1: R23I^T against S. aureus (129B Strain) shows ↑ (reverse effect).
Table 1: R23I^T against E. coli (MG1655 Strain) shows ↑ (reverse effect).
Table 1: R23I^T against P. aeruginosa (2943 Strain) shows ↓ (10 mg/mL).
Table 2: R23I^T at 1 mg/mL against MRSA shows + (inhibition zone).
Table 2: R23I^T at 0.1 mg/mL against MRSA shows − (no inhibition zone).
Table 2: R23I^T at 0.01 mg/mL against MRSA shows − (no inhibition zone).
Table 2: R23I^T at 0.001 mg/mL against MRSA shows − (no inhibition zone).
Table 2: R23I^T at 1 mg/mL against S. aureus 129B shows + (inhibition zone).
Table 2: R23I^T at 0.1 mg/mL against S. aureus 129B shows − (no inhibition zone).
Table 2: R23I^T at 0.01 mg/mL against S. aureus 129B shows − (no inhibition zone).
Table 2: R23I^T at 0.001 mg/mL against S. aureus 129B shows − (no inhibition zone).
Table 2: R23I^T at 1 mg/mL against E. coli MG1655 shows − (no inhibition zone).
Table 2: R23I^T at 0.1 mg/mL against E. coli MG1655 shows − (no inhibition zone).
Table 2: R23I^T at 0.01 mg/mL against E. coli MG1655 shows − (no inhibition zone).
Table 2: R23I^T at 0.001 mg/mL against E. coli MG1655 shows − (no inhibition zone).
Table 2: R23I^T at 1 mg/mL against P. aeruginosa 2943 shows + (inhibition zone).
Table 2: R23I^T at 0.1 mg/mL against P. aeruginosa 2943 shows − (no inhibition zone).
Table 2: R23I^T at 0.01 mg/mL against P. aeruginosa 2943 shows − (no inhibition zone).
Table 2: R23I^T at 0.001 mg/mL against P. aeruginosa 2943 shows − (no inhibition zone).
Table 3: R23I^T against MRSA early biofilm after crystal violet staining shows − (no decrease).
Table 3: R23I^T against S. aureus 129B early biofilm after crystal violet staining shows ↑ (reverse effect).
Table 3: R23I^T against E. coli MG1655 early biofilm after crystal violet staining shows ↑ (reverse effect).
Table 3: R23I^T against P. aeruginosa 2943 early biofilm after crystal violet staining shows − (no decrease).
Table 3: R23I^T against MRSA early biofilm after MTT assay shows ↑ (reverse effect).
Table 3: R23I^T against S. aureus 129B early biofilm after MTT assay shows ↑ (reverse effect).
Table 3: R23I^T against E. coli MG1655 early biofilm after MTT assay shows ↑ (reverse effect).
Table 3: R23I^T against P. aeruginosa 2943 early biofilm after MTT assay shows − (no decrease).
Table 4: R23I^T against MRSA mature biofilm after crystal violet staining shows − (no decrease).
Table 4: R23I^T against S. aureus 129B mature biofilm after crystal violet staining shows − (no decrease).
Table 4: R23I^T against E. coli MG1655 mature biofilm after crystal violet staining shows − (no decrease).
Table 4: R23I^T against P. aeruginosa 2943 mature biofilm after crystal violet staining shows − (no decrease).
Table 4: R23I^T against MRSA mature biofilm after MTT assay shows − (no decrease).
Table 4: R23I^T against S. aureus 129B mature biofilm after MTT assay shows − (no decrease).
Table 4: R23I^T against E. coli MG1655 mature biofilm after MTT assay shows ↑ (reverse effect).
Table 4: R23I^T against P. aeruginosa 2943 mature biofilm after MTT assay shows − (no decrease).
Citation and release provenance
Cite this identity as PepDiana record PEPDIA-PLP-002457, release PepDiana-V1-20260620. Experimental observations retain their paper, mention, and activity-record identifiers.
Record updated: 2026-06-22T07:14:26.229247+00:00